newsfilter
← Latest News
GlobeNewswire·

Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

- Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA - Lead target and